Huangqi Sanxian decoction is involved in gene regulation of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in osteoblasts

doi:10.3969/j.issn.2095-4344.2013.11.006

Abstract

Abstract:

BACKGROUND: Long-term clinical research has demonstrated that Huangqi Sanxian decoction exerts a certain curative effect on osteoporosis. In addition, experimental studies have also showed that Huangqi Sanxian decoction can improve the biomechanical indexes in experimental animals. The present study aimed to investigate the effect of Huangqi Sanxian decoction on osteoblasts in the cellular level.
OBJECTIVE: To observe the effects of Huangqi Sanxian decoction on gene regulation of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in osteoblasts cultured in vitro and to investigate the action mechanism underlying the curative effect of Huangqi Sanxian decoction on osteoporosis.
METHODS: Huangqi Sanxian decoction, Xianlinggubao capsule containing serum and blank serum were prepared to intervening osteoblasts from newborn Sprague-Dawley rats cultured in vitro. Cellular morphology was observed, and western blot analysis and determination of protein concentration were used to observe the effects of drug-containing serum on osteoblast proliferation, gene expression of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in osteoblasts cultured in vitro.
RESULTS AND CONCLUSION: After drug intervention, osteoblasts were spindle-shaped and trabs-shaped, which were concentrated and confluent with undefined boundary. Huangqi Sanxian decoction could increased the protein expression of osteoprotegerin in osteoblasts (P < 0.01), and also increased the protein expression of receptor activator of nuclear factor kappa B ligand (P < 0.01) to increase ratio of osteoprotegerin/receptor activator of nuclear factor kappa B ligand (P < 0.01). Huangqi Sanxian decoction can achieve the therapeutic effect on osteoporosis through regulating the expression of osteoprotegerin and receptor activator of nuclear factor kappa B ligand.

Key words: tissue construction, bone tissue construction, Huangqi Sanxian decoction, supplementing kidney and promoting blood circulation, osteoblasts, osteoprotegerin, osteoprotegerin ligand, osteoporosis, cell culture, osteoclasts, bone resorption, bone formation, provincial grants-supported paper, tissue construction-containing paper

CLC Number:

R318

Li Xiao-min, Lu Chang-jun, Zhou Yan-fang, Zhou Zhi-kun, Feng Xin, Zheng Li-hua. Huangqi Sanxian decoction is involved in gene regulation of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in osteoblasts[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(11): 1939-1945.

Figures/Tables 9

References

[1] Licata A.Bone density vs bone quality: what's a clinician to do. Cleve Clin J Med. 2009;76(6):331-336.

[2] Zhou ZK,Zhu XQ,Xia LY,et al. Zhongguo Zhongyi Jichu Yixue Zazhi. 2001;7(9):49-50. 周志昆,朱学强,夏凌云,等.补肾活血法治疗绝经后骨质疏松症30例[J].中国中医基础医学杂志,2001,7(9):49-50.

[3] Xu ZM,Zhou ZK. Zhongyiyao Daobao. 2009;15(5):9-11. 徐忠明,周志昆.黄芪三仙汤治疗绝经后骨质疏松症36例临床研究[J].中医药导报,2009,15(5):9-11.

[4] Zhou Y. Shijiazhuang:Hebei Yike Daxue. 2005:19-20. 周游.补肾方药对成骨细胞增殖、分化和OPG、RANKL mRNA表达的影响[D]. 石家庄:河北医科大学,2005:19-20.

[5] Liu L,Chang H,Huang GW,et al. Tianjin Yike Daxue Xuebao. 2004;10(1):39-40. 刘莉,常红,黄国伟,等.体外培养大鼠成骨细胞实验模型的建立[J].天津医科大学学报,2004,10(1):39-40.

[6] Cai XX, Luo E, Yuan Q.Interaction between Schwann cells and osteoblasts in vitro.Int J Oral Sci. 2010;2(2):74-81.

[7] Liu YQ. Wulumuqi:Xinjiang Yike Daxue. 2007:7-8. 刘岳强. 氟对体外培养的成骨细胞中Ras基因表达的影响[D]. 乌鲁木齐:新疆医科大学,2007:7-8.

[8] Li YC,Li XH,Gao TL,et al. Shanghai Kouqiang Yixue. 2009; 18(6):624-629. 李蕴聪,李晓红,高陶磊,等.辛伐他汀对大鼠颅骨成骨细胞生物学特性的影响[J].上海口腔医学,2009,18(6):624-629.

[9] Zhang YH.Taiyuan: Shanxi Yike Daxue. 2010: 6-7. 张艳红. rhIGF-1对成骨细胞增殖、BMP-2及Cbfa1基因表达的影响[D].太原:山西医科大学,2010: 6-7.

[10] Tang WJ. Shanghai:Fudan Daxue. 2010:11-13. 唐雯菁.成骨细胞FGF23的表达与局部调节研究[D].上海:复旦大学,2010:11-13.

[11] Liu YS. Changsha:Zhongnan Daxue. 2007:6-7. 刘幼硕.脂联素调节成骨细胞OPG/RANKL的表达和TIMP-3诱导成骨细胞凋亡[D].长沙:中南大学,2007:6-7.

[12] Hofbauer LC, Heufelder AE. Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab. 2000; 85(7):2355-2363.

[13] Kwan Tat S, Padrines M, Théoleyre S,et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15(1): 49-60.

[14] Clohisy D.Cellular mechanisms of osteolysis. J Bone Joint Surg Am. 2003;85-A Suppl 1:S4-6.

[15] Yu FL. Beijing:Zhongguo Zhongyi Kexueyuan. 2007. 于福禄.滋补肾阴法和温补肾阳法对去卵巢所致骨质疏松大鼠OPG、RANKL表达的影响[D].北京:中国中医科学院,2007.